ReviewJPRAS open2026
Free functional muscle transfer after oncologic extremity reconstruction: A systematic review.
Review in JPRAS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Limb-salvage surgery for extremity sarcoma increasingly prioritizes preservation of meaningful motor function, yet oncologic resections often require removal of major musculotendinous units, resulting in severe disability despite limb preservation. Free functional muscle transfer (FFMT) offers a reconstructive option capable of restoring active motion through microvascular transfer and reinnervation of a donor muscle. Methods: A PRISMA-guided, OSF-registered systematic review was performed to evaluate outcomes of FFMT following oncologic extremity resection. Primary endpoints were flap survival and functional strength recovery (MRC/MMT), with secondary outcomes including complications and tumor recurrence. Outcomes were synthesized descriptively using pooled proportions with Wilson 95% confidence intervals. Results: Twenty-two studies comprising 82 cases met inclusion criteria. Flap survival was reported in 77 cases, with 100% survival (77/77; 95% CI 95.3-100.0). Complication outcomes were available in 60 cases, with a pooled complication rate of 26.67% (16/60; 95% CI 17.1-39.0%), most commonly involving wound-related events. Strength outcomes were most frequently in the MRC/MMT >3 to ≤4 range (36/82; 43.9%), while 15.9% achieved >4 to ≤5 strength. Mean strength varied by donor muscle, with vastus lateralis (4.21) and rectus femoris (4.17) demonstrating higher averages than latissimus dorsi (3.55) and gracilis (3.60), though subgroup sample sizes were small. Tumor recurrence was uncommon among reported cases. Conclusions: FFMT demonstrates high flap reliability and frequently meaningful strength recovery following oncologic extremity resection, supporting its role as a cornerstone technique for functional limb salvage. However, the evidence base remains limited by small heterogeneous series and incomplete outcome reporting, underscoring the need for standardized functional endpoints and prospective multicenter data collection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.